PD-161570

N/A

Report date: 2022/10/25 13:04:45
NME

Base Information

Drug NamePD-161570
Drug Alias NamePD-161570
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor inhibitorsFibroblast growth factor receptor 1 antagonistsTyrosine-protein kinase SRC inhibitors +[4] 
TargetsPlatelet-derived growth factor receptorFibroblast growth factor receptor 1Tyrosine-protein kinase SRC +[4] 
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesParke-Davis GmbhPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesParke-Davis Gmbh
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A